| Entry |
|
|---|
| Name |
Trospium chloride (JAN/USP/INN);
Spasmex (TN);
Spasmoplex (TN) |
|---|
| Product |
|
|---|
| Generic |
TROSPIUM CHLORIDE (Actavis Pharma), TROSPIUM CHLORIDE (BluePoint Laboratories), TROSPIUM CHLORIDE (Bluepoint Laboratories), TROSPIUM CHLORIDE (Bryant Ranch Prepack), TROSPIUM CHLORIDE (Bryant Ranch Prepack), TROSPIUM CHLORIDE (CIPLA USA INC.,), TROSPIUM CHLORIDE (Exelan Pharmaceuticals), TROSPIUM CHLORIDE (Glenmark Pharmaceuticals), TROSPIUM CHLORIDE (Golden State Medical Supply), TROSPIUM CHLORIDE (Granules Pharmaceuticals), TROSPIUM CHLORIDE (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals), TROSPIUM CHLORIDE (Major Pharmaceuticals), TROSPIUM CHLORIDE (Paddock Laboratories), TROSPIUM CHLORIDE (Paddock Laboratories), TROSPIUM CHLORIDE (Proficient Rx LP), TROSPIUM CHLORIDE (Slate Run Pharmaceuticals), TROSPIUM CHLORIDE ER (35573) |
|---|
| Formula |
C25H30NO3. Cl
|
|---|
| Exact mass |
427.1914
|
|---|
| Mol weight |
427.9636
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG01491 Muscarinic cholinergic receptor antagonist
|
|---|
| Remark |
|
|---|
| Efficacy |
Overactive bladder agent, Muscarinic acetylcholine receptor antagonist |
|---|
| Comment |
Treatment of urinary incontinence
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07220 | Cholinergic and anticholinergic drugs |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
G GENITO URINARY SYSTEM AND SEX HORMONES
G04 UROLOGICALS
G04B UROLOGICALS
G04BD Urinary antispasmodics
G04BD09 Trospium
D01103 Trospium chloride (JAN/USP/INN) <US>
USP drug classification [BR:br08302]
Genitourinary Agents
Antispasmodics, Urinary
Trospium
D01103 Trospium chloride (JAN/USP/INN)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Acetylcholine (muscarinic)
CHRM2
D01103 Trospium chloride (JAN/USP/INN) <US>
CHRM3
D01103 Trospium chloride (JAN/USP/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01103
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01103
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 30
1 X Cl 11.7779 -16.5523 #-
2 N2y N 14.0700 -15.8200 #+
3 C1x C 15.1900 -14.9800
4 C1x C 14.7700 -13.6500
5 C1x C 13.3700 -13.6500
6 C1x C 12.9500 -15.0500
7 O7a O 18.1300 -19.5300
8 C1y C 17.4300 -18.3400
9 C1x C 16.3800 -16.8000
10 C1x C 16.3800 -17.8500
11 C1y C 14.9100 -16.8000
12 C1y C 14.8400 -17.8500
13 C1x C 13.8600 -17.3600
14 C1x C 13.3700 -18.4800
15 C7a C 19.5300 -19.5300
16 O6a O 20.2300 -20.7424
17 C1d C 20.2300 -18.3176
18 C8y C 21.8398 -18.3176
19 C8y C 19.5396 -17.1221
20 O1a O 20.9300 -17.1051
21 C8x C 20.2251 -15.9347
22 C8x C 19.5250 -14.7223
23 C8x C 18.1250 -14.7224
24 C8x C 17.4396 -15.9097
25 C8x C 18.1396 -17.1221
26 C8x C 22.5497 -19.5468
27 C8x C 23.9497 -19.5466
28 C8x C 24.6496 -18.3341
29 C8x C 23.9397 -17.1049
30 C8x C 22.5397 -17.1051
BOND 33
1 3 4 1
2 8 9 1
3 8 10 1
4 9 11 1
5 10 12 1
6 11 2 1
7 11 13 1
8 12 14 1
9 12 2 1
10 13 14 1
11 8 7 1 #Down
12 4 5 1
13 5 6 1
14 6 2 1
15 2 3 1
16 7 15 1
17 15 16 2
18 15 17 1
19 17 18 1
20 17 19 1
21 17 20 1
22 19 21 2
23 21 22 1
24 22 23 2
25 23 24 1
26 24 25 2
27 19 25 1
28 18 26 2
29 26 27 1
30 27 28 2
31 28 29 1
32 29 30 2
33 18 30 1
|
|---|
